Cytoreductive treatment patterns among US veterans with polycythemia vera
Open Access
- 4 May 2018
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 528
Abstract
Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased thrombotic and cardiovascular risk, which are key contributors to patient morbidity and mortality. The Veterans Health Administration (VHA) is the largest integrative health network in the United States. Available data concerning patients with PV in this population are limited. This retrospective observational study evaluated the characteristics, management, and outcomes of patients with PV in the VHA Medical SAS® Dataset (October 1, 2005, to September 30, 2012). Inclusion criteria were ≥ 2 claims for PV (ie, PV diagnostic code was recorded) ≥30 days apart during the identification period, age ≥ 18 years, and continuous health plan enrollment from ≥12 months before the index date until the end of follow-up. All data were analyzed using descriptive statistics. The analysis included 7718 patients (median age, 64 years; male, 98%; white, 64%). The most common comorbidities before the index date were hypertension (72%), dyslipidemia (54%), and diabetes (24%); 33% had a history of smoking. During the follow-up period (median, 4.8 years), most patients did not receive treatment with cytoreductive therapy, including phlebotomy (53%), or antiplatelet agents, such as aspirin (57%). The thrombotic and cardiovascular event rates per 1000 patient-years were 60.5 and 83.8, respectively. Among patients who received cytoreductive treatment, the thrombotic event rate was 48.9 per 1000 patient-years. The overall mortality rate was 51.2 per 1000 patient-years. The notable rates of thrombotic and cardiovascular events observed in this analysis, even among patients receiving cytoreductive treatment, highlight the important unmet clinical needs of patients with PV in the VHA.Keywords
Funding Information
- Incyte Corporation
This publication has 26 references indexed in Scilit:
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyLeukemia, 2013
- Cardiovascular Events and Intensity of Treatment in Polycythemia VeraNew England Journal of Medicine, 2013
- Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980Journal of Clinical Oncology, 2011
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNetJournal of Clinical Oncology, 2011
- Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaBlood, 2007
- Bringing the War Back HomeArchives of internal medicine (1960), 2007
- Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia VeraJournal of Clinical Oncology, 2005
- Efficacy and Safety of Low-Dose Aspirin in Polycythemia VeraNew England Journal of Medicine, 2004
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994
- A chronic disease score from automated pharmacy dataJournal of Clinical Epidemiology, 1992